.Pharmacolibrary.Drugs.C_CardiovascularSystem.C02A_AntiadrenergicAgentsCentrallyActing.C02AB01_MethyldopaLevorotatory.MethyldopaLevorotatory .Pharmacolibrary.Drugs.C_CardiovascularSystem.C02A_AntiadrenergicAgentsCentrallyActing.C02AB01_MethyldopaLevorotatory.MethyldopaLevorotatory| name: | MethyldopaLevorotatory |
| ATC code: | C02AB01 | route: | oral |
| n-compartments | 1 |
Methyldopa is a centrally acting antihypertensive agent, primarily used in the management of hypertension, especially in pregnant women (pre-eclampsia). It functions as a prodrug, metabolized to alpha-methylnorepinephrine, an alpha-2 adrenergic agonist. Methyldopa is approved and used clinically, especially for hypertension in pregnancy.
Pharmacokinetic parameters for healthy adult volunteers following single oral dose administration.
Othman, AA, & Dutta, S (2014). Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. British journal of clinical pharmacology 78(1) 94–105. DOI:10.1111/bcp.12324 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24433449
Cabreira, V, et al., & Massano, J (2019). Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs 79(6) 593–608. DOI:10.1007/s40265-019-01098-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/30905034
Stocchi, F, & Vacca, L (2019). A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease. Minerva medica 110(6) 575–585. DOI:10.23736/S0026-4806.19.06330-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31965781